Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe

Back

EHRA Premium Access

Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe

Session: Prevention of stroke in atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Doctor T. de Vries (Amsterdam, NL)

Event: EHRA 2021

Congress Presentation

Add to my library

About the speaker

Doctor Tim Anthonie Christiaan de Vries

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

0 follower

6 more presentations in this session

Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study

Speaker: Professor J. De Groot (Amsterdam, NL)

Contemporary data evaluating 1-year clinical outcomes in patients with atrial fibrillation and coexisting valvular heart disease: the ETNA-AF-Europe study

Speaker: Professor F. Ricci (Chieti, IT)

Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation

Speaker: Doctor S. Lee (Seoul, KR)

Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF

Speaker: Doctor D. Morrone (Pisa, IT)

Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program

Speaker: Doctor L. Dinshaw (Wismar, DE)

Access the full session

Prevention of stroke in atrial fibrillation

Speakers: Doctor T. de Vries, Professor J. De Groot, Professor F. Ricci, Doctor S. Lee, Doctor D. Morrone...

Access

About the event

EHRA 2021

23 April - 25 April 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources